The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

Joanne Haviland, John R. Owen, John Dewar, +13

The Lancet Oncology

Radiation MedicineRadiation TherapyBreast RadiotherapyMedicineBrachytherapy +9

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Jayant S. Vaidya, Frederik Wenz, Max Bulsara, +26

The Lancet

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

Jayant S. Vaidya, David Joseph, Jeffrey Tobias, +21

The Lancet

Surgical OncologyBreast OncologyRadiation TherapyTargit-a TrialMedicine +5

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Charlotte E. Coles, Clare Griffin, Anna M. Kirby, +50

The Lancet

aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Richard Gray, Daniel Rea, Kelly Handley, +17

Journal of Clinical Oncology

Breast OncologyCancer ManagementEpidemiology Of CancerGynecologyPharmacotherapy +15

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

J.F.R. Robertson, Antonio Llombart‐Cussac, Janusz Rolski, +5

Journal of Clinical Oncology

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

Sirwan Hadad, Takayuki Iwamoto, Lee B. Jordan, +10

Breast Cancer Research and Treatment

Surgical OncologyOncologyBiological EffectsBreast OncologyMedicine +8

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Alastair M. Thompson, Lee B. Jordan, Philip Quinlan, +4

Breast Cancer Research

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl, +5

Journal of Clinical Oncology

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Michael Wallington, Emma B. Saxon, Martine Bomb, +11

The Lancet Oncology